全文获取类型
收费全文 | 457542篇 |
免费 | 33272篇 |
国内免费 | 9597篇 |
专业分类
耳鼻咽喉 | 5803篇 |
儿科学 | 8962篇 |
妇产科学 | 10994篇 |
基础医学 | 61851篇 |
口腔科学 | 13215篇 |
临床医学 | 41714篇 |
内科学 | 89056篇 |
皮肤病学 | 9138篇 |
神经病学 | 31899篇 |
特种医学 | 16892篇 |
外国民族医学 | 138篇 |
外科学 | 67829篇 |
综合类 | 24681篇 |
一般理论 | 77篇 |
预防医学 | 22516篇 |
眼科学 | 12248篇 |
药学 | 39617篇 |
83篇 | |
中国医学 | 7909篇 |
肿瘤学 | 35789篇 |
出版年
2022年 | 2898篇 |
2021年 | 6403篇 |
2020年 | 5471篇 |
2019年 | 5697篇 |
2018年 | 7415篇 |
2017年 | 6137篇 |
2016年 | 5792篇 |
2015年 | 7903篇 |
2014年 | 10717篇 |
2013年 | 11566篇 |
2012年 | 16166篇 |
2011年 | 17311篇 |
2010年 | 10632篇 |
2009年 | 9320篇 |
2008年 | 13840篇 |
2007年 | 14549篇 |
2006年 | 14674篇 |
2005年 | 13802篇 |
2004年 | 11429篇 |
2003年 | 11105篇 |
2002年 | 10325篇 |
2001年 | 29944篇 |
2000年 | 30592篇 |
1999年 | 25573篇 |
1998年 | 6349篇 |
1997年 | 5387篇 |
1996年 | 4738篇 |
1995年 | 4478篇 |
1994年 | 3931篇 |
1993年 | 3347篇 |
1992年 | 16568篇 |
1991年 | 15250篇 |
1990年 | 14560篇 |
1989年 | 14303篇 |
1988年 | 12864篇 |
1987年 | 12273篇 |
1986年 | 11258篇 |
1985年 | 10456篇 |
1984年 | 6967篇 |
1983年 | 5626篇 |
1982年 | 2742篇 |
1979年 | 5492篇 |
1978年 | 3345篇 |
1977年 | 2963篇 |
1975年 | 2636篇 |
1974年 | 3064篇 |
1973年 | 2863篇 |
1972年 | 2828篇 |
1971年 | 2773篇 |
1969年 | 2543篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Post-induction hypotension is common and associated with postoperative complications. We hypothesised that pneumatic leg compression reduces post-induction hypotension in elderly patients undergoing robot-assisted laparoscopic prostatectomy. In this double-blind randomised study, patients were allocated randomly to the pneumatic leg compression group (n = 50) or control (n = 50). In the intervention group, pneumatic leg compression was initiated before induction of anaesthesia. In the control group, pneumatic leg compression was initiated 20 min after anaesthesia induction. The primary outcome was the incidence of post-induction hypotension in these groups. Post-induction hypotension was defined as systolic blood pressure < 90 mmHg during the first 20 min after induction. Haemodynamic variables and area under the curve of post-induction systolic blood pressure over time were assessed. Complications associated with pneumatic leg compression were recorded, including: peripheral neuropathy; compartment syndrome; extensive bullae beneath the leg sleeves; and pulmonary thromboembolism. The incidence of post-induction hypotension decreased in the pneumatic leg compression group compared with that in the control group; 5 (10%) vs. 29 (58%), respectively, p < 0.001. In the pneumatic leg compression group, the lowest systolic, diastolic and mean blood pressures 20 min after induction of anaesthesia were significantly greater than the control group. Pneumatic leg compression resulted in an increased area under the curve of systolic blood pressure in the first 20 min after induction, p = 0.001. There were no pneumatic leg compression-related complications. Pneumatic leg compression reduced post-induction hypotension in elderly patients undergoing robot-assisted laparoscopic prostatectomy, suggesting that it is an effective and safe intervention to prevent post-induction hypotension among elderly patients undergoing general anaesthesia. 相似文献
2.
3.
4.
Buket Bakan Fatih Oltulu Yeliz Y?ld?r?m Altu? Yava?o?lu Sinan Akg?l Nefise ülkü Karabay Yava?o?lu 《Arhiv za higijenu rada i toksikologiju》2023,74(3):207
The aim of this safety study in mice was to determine in vivo toxicity and biodistribution potential of a single and multiple doses of L-glutamic acid-g-p(HEMA) polymeric nanoparticles as a drug delivery system. The single dose did not cause any lethal effect, and its acute oral LD50 was >2.000 mg/kg body weight (bw). Multiple doses (25, 50, or 100 mg/kg bw) given over 28 days resulted in no significant differences in body and relative organ weights compared to control. These results are supported by biochemical and histological findings. Moreover, nanoparticle exposure did not result in statistically significant differences in micronucleus counts in bone marrow cells compared to control. Nanoparticle distribution was time-dependent, and they reached the organs and even bone marrow by hour 6, as established by ex vivo imaging with the IVIS® spectrum imaging system. In conclusion, L-glutamic acid-g-p(HEMA) polymeric nanoparticles appear biocompatible and have a potential use as a drug delivery system.KEY WORDS: biocompatibility, blood biochemistry, genotoxicity, histology, in vivo toxicity, micronucleus test, polymers 相似文献
5.
目的 了解农村老年人的老化期望现状,分析其影响因素,为针对干预提供参考。
方法 采用一般资料调查表、UCLA孤独感量表简化版、老化期望量表、简版自我感知老化量表对199名农村老年人进行问卷调查。
结果 老化期望总分为32.72±9.18,孤独感得分为15.11±3.82,自我感知老化得分为52.75±2.76;多元线性回归分析显示,性别、婚姻状况、患慢性病种数、独居、孤独感、自我感知老化及经济来源是农村老年人老化期望的影响因素(调整R2=0.612,均P<0.05)。
结论 农村老年人的老化期望水平较低,女性、孤独、无配偶、患慢性病较多、老化态度消极及低收入人群是关注的重点。 相似文献
6.
目的探讨超微经皮肾镜取石术(UMP)应用于直径1.5~2.5 cm肾及输尿管上段结石患者中的安全性和有效性。方法回顾性分析2018年6月-2020年6月宿迁市第一人民医院收治的60例直径为1.5~2.5 cm肾及输尿管上段结石患者的临床资料,均采用UMP治疗,分析患者手术时间、住院时间、手术成功率、结石清除率、并发症发生率及额外镇痛药使用情况。结果60例患者均一期建立通道并顺利完成手术。所有患者均未行单通道手术,未接受输血,无毗邻脏器损伤(肠道、肝脏和脾脏等),无血气胸发生;存在尿外渗或者有明显症状的腹膜后灌注液患者3例(5.0%),均行保守治疗好转;发热(体温高于38℃)5例(8.3%),均对症治疗后好转;无感染性休克患者。手术时间为35~98 min,平均(56.1±21.3)min;术后住院天数为3~8 d,平均(4.1±1.8)d;术后立即评估结石清除率为85.0%(51/60),术后1个月评估结石清除率为91.7%(55/60);术后镇痛药使用率为15.0%(9/60)。结论UMP是治疗直径1.5~2.5 cm肾及输尿管上段结石安全、有效的治疗方法之一,值得临床推广。 相似文献
7.
卫逸涛肖惠敏谢银环孙丽军 《中华健康管理学杂志》2022,(8):547-552
目的了解老年人生命晚期获知疾病相关信息意向及影响因素。方法2016年10月至2017年6月,采用生命晚期疾病信息意向问卷,利用方便抽样法对福州市中心城区7所养老机构及15个社区的414例年龄≥60岁的老年人进行横断面调查,采用单因素分析、多元线性回归与有序多分类logistic回归分析老年人对疾病相关信息的需求水平、获知程度意向及其影响因素。结果414例老年人疾病相关信息需求得分为(17.1±4.9)分;48.8%(202/414)希望详尽知晓,30.7%(127/414)希望选择性了解,20.5%(85/414)不想知道任何信息;多元线性回归分析显示,年龄、文化程度、是否接受/见过其他生命维持治疗(LSTs)是影响老年人疾病相关信息需求水平的主要因素(标准化回归系数分别为-0.141、0.116、0.115,均P<0.05);有序多分类logistic分析显示,年龄(以60~69岁为参照,70~79岁:OR=0.544,95%CI:0.310~0.957;80~89岁:OR=0.526,95%CI:0.289~0.956)、文化程度(以小学及以下为参照,大专及以上:OR=2.166,95%CI:1.093~4.290)、主要生活费来源(以其他补贴为参照,家人支持:OR=7.303,95%CI:1.157~46.108;退休金:OR=9.288,95%CI:1.502~57.415;公积金/储蓄:OR=15.676,95%CI:2.122~115.793)、是否接受/见过其他LSTs(以是为参照,OR=1.985,95%CI:1.150~3.425)是影响老年人疾病相关信息获知程度意向的主要因素。结论老年人生命晚期获知疾病相关信息的意向程度较高,年龄、文化程度、主要生活费来源、是否接受/见过其他生命维持治疗等是其主要影响因素。 相似文献
8.
Preliminary study on blood coagulation and hemostatic effect and acute toxicity of Oxalis corniculata L. ethanol extract 下载免费PDF全文
In the present study, we aimed to observe the effects of ethanol extract of Oxalis corniculata L. on bleeding time (BT) and coagulation time (CT) and determine its acute toxicity in mice. Firstly, the ethanol extract of O. corniculata was administered to 40 mice, which were randomly divided into the normal control group, Yunnan Baiyao control group, low-dose group, and high-dose group. The low-dose (0.6 g/kg) and high-dose (1.2 g/kg) groups received ethanol extract of O. corniculata by gavage, and the BT and CT of the mice were measured by the slide method and tail clipping method, respectively. Secondly, the median lethal dose method was used with 50 mice to observe the physiological state, poisoning reaction, and death of the mice after intragastric administration. Finally, on the 14th day of the experiment, a necropsy was performed to observe any abnormality of the organs. In conclusion, in the coagulation and hemostasis tests, there were no statistical differences between the groups (P > 0.05), while there was a significant dose-response relationship, and the BT and CT were significantly shorter than those of the negative control group, which were comparable to the Yunnan Baiyao control group. Moreover, in the acute toxicity test, the median lethal dose of ethanol extract of O. corniculata was 6.0291 g/kg, with a 95% confidence interval of 5.3065–6.7829 mg/kg. 相似文献
9.
目的 本研究旨在探讨原发性高血压患者脉图参数与心血管危险分层的相关性,为原发性高血压患者心血管风险事件预警提供中医特色的依据。方法 采集435例原发性高血压患者的症状体征、脉象信息、生化指标等,分为低中危组、高危组、很高危组,采用单因素方差分析、秩和检验、有序logistic回归分析等方法,探讨原发性高血压患者脉图参数与心血管危险分层的相关性。结果 ①高血压低中危组→高危组→很高危组患者病程逐渐延长,两两组间比较有统计学差异;②高血压低中危组→高危组→很高危组患者的脉图参数H3/H1、H4/H1逐渐上升;高血压患者很高危组H5/H1、T1/T低于低中危组;③有序logistic回归分析结果显示,脉图参数T1、T4、T5、T为影响因素。结论 病程、血脂、肾功能是高血压患者心血管危险分层的影响因素之一。心血管危险分层等级的升高与脉图参数H3/H1、H4/H1、T5、T的升高及H5/H1、T4、T1的降低相关,说明脉图能一定程度上反映原发性高血压患者血管壁增厚、血管内壁受损、血管硬化及左心室收缩功能的减退程度。 相似文献
10.
Laurien J. Zeverijn Eleonora J. Looze Subotheni Thavaneswaran J. Maxime van Berge Henegouwen Robert J. Simes Louisa R. Hoes Katrin M. Sjoquist Hanneke van der Wijngaart Lucille Sebastian Birgit S. Geurts Chee K. Lee Gijsbrecht F. de Wit David Espinoza Paul Roepman Frank P. Lin Anne M. L. Jansen Wendy W. J. de Leng Vincent van der Noort Lindsay V. M. Leek Filip Y. F. L. de Vos Carla M. L. van Herpen Hans Gelderblom Henk M. W. Verheul David M. Thomas Emile E. Voest 《International journal of cancer. Journal international du cancer》2023,153(7):1413-1422
The Dutch Drug Rediscovery Protocol (DRUP) and the Australian Cancer Molecular Screening and Therapeutic (MoST) Program are similar nonrandomized, multidrug, pan-cancer trial platforms that aim to identify signals of clinical activity of molecularly matched targeted therapies or immunotherapies outside their approved indications. Here, we report results for advanced or metastatic cancer patients with tumors harboring cyclin D-CDK4/6 pathway alterations treated with CDK4/6 inhibitors palbociclib or ribociclib. We included adult patients that had therapy-refractory solid malignancies with the following alterations: amplifications of CDK4, CDK6, CCND1, CCND2 or CCND3, or complete loss of CDKN2A or SMARCA4. Within MoST, all patients were treated with palbociclib, whereas in DRUP, palbociclib and ribociclib were assigned to different cohorts (defined by tumor type and alteration). The primary endpoint for this combined analysis was clinical benefit, defined as confirmed objective response or stable disease ≥16 weeks. We treated 139 patients with a broad variety of tumor types; 116 with palbociclib and 23 with ribociclib. In 112 evaluable patients, the objective response rate was 0% and clinical benefit rate at 16 weeks was 15%. Median progression-free survival was 4 months (95% CI: 3-5 months), and median overall survival 5 months (95% CI: 4-6 months). In conclusion, only limited clinical activity of palbociclib and ribociclib monotherapy in patients with pretreated cancers harboring cyclin D-CDK4/6 pathway alterations was observed. Our findings indicate that monotherapy use of palbociclib or ribociclib is not recommended and that merging data of two similar precision oncology trials is feasible. 相似文献